Peptides

Matches 1 - 50 out of 23,172	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >

Document	Document Title
WO/2024/103167A1	TRIVALENT TUBERCULOSIS VACCINE A multi-valent vaccine is provided which targets the multi-stage life cycle of Mycobacterium species of the tuberculosis complex. The vaccine comprises a transgene that expresses an acute mycobacterial infection-associated antigen such a...
WO/2024/077251A3	INTERLEUKIN-21 MIMETICS Disclosed are de novo designed polypeptide agonists and antagonists of IL-21, conditionally-active IL-21 agonists and antagonists, and methods for using them to treat cancer or to modulate an immune response.
WO/2024/103431A1	METHOD FOR ENHANCING BROAD-SPECTRUM PROPERTY OF VACCINE AGAINST COVID-19 MUTANT STRAINS, AND BROAD-SPECTRUM COVID-19 VACCINE A method for enhancing the broad-spectrum property of a vaccine against COVID-19 mutant strains, and a broad-spectrum COVID-19 vaccine. RBDs of six different COVID-19 mutant strains and six highly conserved CD8+ T cell epitope peptides o...
WO/2024/103579A1	PREPARATION METHOD FOR CORONAVIRUS PSEUDOVIRUS PARTICLE Provided is a preparation method for a coronavirus pseudovirus particle. By means of constructing a plasmid (1): a retroviral vector that removes RT and INT genes, in which a gene sequence of an NC protein of the retroviral vector is rep...
WO/2024/081938A3	PROTEIN SCAFFOLDS FOR DISORDERED REGIONS The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...
WO/2024/104412A1	ATTENUATED INTERFERON PROTEINS AND FRAGMENTS AND MULTIFUNCTIONAL POLYPEPTIDES AND CONJUGATES Provided herein are modified IFNα2b proteins and functional fragments thereof. Also provided are polypeptides, such as bi-functional and multi-functional ones, which further include a biological moiety such as an antibody or antigen-bin...
WO/2024/069240A3	CD38-BINDING FUSION PROTEIN COMBINATION THERAPY Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in co...
WO/2024/107598A1	NOVEL RESISTANCE GENES ASSOCIATED WITH DISEASE RESISTANCE IN SOYBEANS Methods and compositions for identifying, selecting and/or producing a pathogen resistant plant, plant cell or seed (e.g., a legume or soybean plant, plant cell or seed) are provided. Polynucleotides and polypeptides are provided, which ...
WO/2024/103251A1	ANTI-AFP/HLA02 TCR-LIKE ANTIBODY AND USE THEREOF The present application relates to an anti-AFP/HLA02 TCR-like antibody and the use thereof. The antibody can specifically bind to a human AFP158-166/HLA-A0201 complex with a KD value of about 3.1E-09M or less. The present application f...
WO/2024/081940A3	PROTEIN SCAFFOLDS FOR DISORDERED REGIONS The disclosure provides proteins that can be used as scaffolds to bind a specific target, including specific proteins or peptides of interest, as well as fusion proteins with the scaffolds. Such proteins or peptides of interest may inclu...
WO/2024/035955A3	BISPECIFIC ANTIBODIES AND CONSTRUCTS FOR LYSOSOMAL TARGETING DEGRADATION AND METHODS OF USE THEREOF Provided herein are antigen-binding proteins (ABPs) that selectively bind to M6PR and its isoforms and homologs, and compositions comprising the ABPs. Also provided herein are bispecific antigen-binding proteins (ABPs) that selectively b...
WO/2024/102977A1	STABLE PRODUCTION SYSTEMS FOR ADENO-ASSOCIATED VIRUS PRODUCTION Disclosed herein are genetically engineered cells for AAV production. The genetically engineered cell comprises molecular systems for temporal control of expression of genes required for AAV production. Also disclosed herein are methods ...
WO/2024/099975A1	ARTIFICIAL AMINO ACID CONTAINING LIPO-OLIGOMERS FOR RIBONUCLEOPROTEIN DELIVERY The invention relates to nanoparticles for Cas protein/gRNA ribonucleoprotein (RNP) complex, siRNA or PMO delivery comprising one or more Cas protein/gRNA RNP complex(es), siRNA(s) or PMO(s) as cargo; and a carrier comprising a sequence-...
WO/2024/102972A1	BASE EDITING OF TRANSTHYRETIN GENE Provided herein are compositions for gene modification related to base editor systems, and methods of using the same to treat or prevent conditions associated with the extracellular deposition in various tissues of amyloid fibrils formed...
WO/2024/102943A1	ARMED CHIMERIC RECEPTORS AND METHODS OF USE THEREOF Described herein are immunoresponsive cells engineered to express cytokines, chimeric receptors, and synthetic transcription factor systems. Also described herein are nucleic acids, cells, and methods directed to the same.
WO/2024/098383A1	PROTEIN MUTANT AND USE THEREOF IN TREATMENT OF DISEASE RELATED TO HBB GENE MUTATION Disclosed are a protein mutant with a sequence having more than 80% identity to SEQ ID NO. 1, a gRNA used in combination with the protein mutant, a gene editing system, an expression vector, a modified cell, a pharmaceutical composition,...
WO/2024/102764A1	COMPOSITIONS COMPRISING NEOANTIGENS AND METHODS OF ENHANCING ANTI-PD1 THERAPY The disclosure relates to methods of treating cancer in a subject administering nucleic acid molecules comprising a nucleic acid sequence encoding a plurality of neoantigens. Vaccines, compositions comprising coding regions encoding neoa...
WO/2024/098939A1	BIFUNCTIONAL FUSION PROTEIN AND USE THEREOF Provided is a bifunctional fusion protein, comprising a first domain specifically recognizing interleukin-6 receptor (IL-6R), and a second domain specifically binding to cell surface protein CD47. Also provided is a method of using said ...
WO/2024/099320A1	COMPLEMENT-INHIBITORY HYBRID PROTEIN MUTANT AND ANTIBODY FUSION PROTEIN THEREOF A hybrid protein containing a CFH functional unit and a DAF functional unit, and a mutant thereof, an encoding nucleic acid thereof, and a method and the use thereof for treating diseases or conditions related to a complement system; and...
WO/2024/101433A1	GLYCOSYLATED NEUROPEPTIDE DERIVATIVE INCLUDING NEUROPEPTIDE SEQUENCE AND SUGAR CHAIN, PHARMACEUTICAL COMPOSITION, TRANSNASAL/NASAL DRIP FORMULATION, AND USE OF GLYCOSYLATED NEUROPEPTIDE DERIVATIVE A glycosylated neuropeptide derivative comprising a neuropeptide sequence, a membrane-penetration-promoting sequence, an endosomal-escape-promoting sequence, and a sugar chain.
WO/2024/102436A1	SYSTEM FOR MODULATING RECEPTOR TYROSINE KINASE SIGNALING AND METHODS OF USE THEREOF Provided herein is an engineered controllable membrane targeting system based on triggered exposure of a cryptic acylation signal, a calcium-regulated protease that can be used to expose this cryptic acylation signal, a means of coupling...
WO/2024/100557A1	ANTI-GPNMB CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE Provided are glycoprotein NMB (GPNMB)-binding chimeric antigen receptors (CARs). In some embodiments, a CAR of the present disclosure comprises an extracellular GPNMB-binding domain (e.g., a single chain antibody, such as an scFv), a tra...
WO/2024/101434A1	PHYSIOLOGICALLY-ACTIVE PEPTIDE DERIVATIVE FOR TREATMENT OF EYE DISEASES, PHARMACEUTICAL COMPOSITION, NASAL/NASAL DROP PREPARATION, AND USE OF PHYSIOLOGICALLY-ACTIVE PEPTIDE DERIVATIVE This physiologically-active peptide derivative for the treatment of eye diseases comprises a physiologically-active peptide sequence and a functional sequence comprising a membrane permeation-promoting sequence and an endosomal escape-pr...
WO/2024/103049A1	CD33 SPECIFIC EXOSOMES AND USES THEREOF Disclosed are exosomes comprising an extracellular CD33 binding motif fused to a transmembrane protein. Disclosed are methods of making a cell derived exosome comprising: transfecting a plasmid into cells, wherein the plasmid comprises a...
WO/2024/102954A1	ACTIVATION INDUCED CLIPPING SYSTEM (AICS) Disclosed are nucleic acids encoding fusion proteins containing a target binding domain, a cleavage domain cleavable by A Disintegrin and Metalloproteinase (ADAM) 17, and a transmembrane domain.
WO/2024/097877A1	ANTI-ZP4 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF Provided herein are ZP4 antibodies and ZP4-specific chimeric antigen receptors (CARs). Further provided herein are immune cells expressing the ZP4-specific CARs and methods of treating cancer by administering the ZP4-specific CAR immune ...
WO/2024/094159A1	SINGLE DOMAIN ANTIBODY TARGETING HUMAN ROR1 Provided in the present application are a single domain antibody targeting the ROR1 protein as well as a chimeric antigen receptor (CAR) and CAR-T cell comprising the single domain antibody. Also provided are uses of the single domain an...
WO/2024/093147A1	ANTIBODY SPECIFICALLY BINDING TO V5 EXON OF CD44, AND USE THEREOF The present invention relates to an antibody specifically binding to the v5 exon of human CD44 or a fragment thereof. The present invention also relates to a chimeric antigen receptor molecule comprising the antibody or the fragment ther...
WO/2024/094002A1	FRUCTOSE-1,6-DIPHOSPHATE OPTICAL PROBE, AND PREPARATION METHOD THEREFOR AND USE THEREOF The present invention relates to a fructose diphosphate optical probe. Specifically, provided in the present invention is a fructose diphosphate optical probe, which comprises a fructose-1,6-diphosphate sensitive polypeptide and an optic...
WO/2024/092769A1	MODIFIED COVALENTLY-LINKED PILI AND RECOMBINANT BACTERIA COMPRISING THE SAME Provided is a fusion polypeptide comprising a carrier protein and a polypeptide of interest, wherein the polypeptide of interest is fused to a terminus of the carrier protein or inserted into the carrier protein, and wherein the carrier ...
WO/2024/097938A1	COMPOSITIONS AND METHODS FOR INCREASING TRANSPORT INTO THE BRAIN The present disclosure generally relates to compositions and methods for enhancing transportof molecules into the brain using modified IgG Fc regions, and methods of producing and using molecules comprising such modified Fc regions.
WO/2024/094224A2	PBASE PROTEIN, FUSION PROTEIN, NUCLEIC ACID, GENE INTEGRATION SYSTEM AND USE Provided in the present invention are a PBase protein, a fusion protein, a nucleic acid, a gene integration system, a gene delivery system and the use. The PBase protein retains the abilities of binding to the ITR sequences of a Piggybac...
WO/2024/094004A1	FULLY HUMAN ANTIBODY TARGETING CD123 AND USE THEREOF The invention belongs to the technical field of cell immune engineering, and particularly relates to a fully human antigen binding fragment and single chain fragment variable targeting CD123, and a use thereof. The single chain fragment ...
WO/2024/093882A1	CD24 BINDING PROTEIN AND USE THEREOF Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of t...
WO/2024/093056A1	KRAS_G12V MUTANT ANTIGEN-SPECIFIC TCR AND REDIRECTED CD4 T CELL CO-EXPRESSING SAME AND CD8 The present invention relates to a T cell receptor (TCR) specifically binding to a KRAS_G12V mutant antigen, a fusion protein or conjugate comprising the TCR, a nucleic acid encoding the TCR and an engineered cell comprising same, and a ...
WO/2024/093554A1	RECOMBINANT SUBUNIT VACCINE AGAINST RSV AND USE THEREOF The present invention relates to the field of biomedicine, in particular to a recombinant subunit vaccine against respiratory syncytial virus (RSV) and a use thereof, and more in particular to a recombinant fusion protein containing the ...
WO/2024/097797A1	BLOCKADE OF CD3 EXPRESSION AND CHIMERIC ANTIGEN RECEPTORS FOR IMMUNOTHERAPY T cells expressing a chimeric antigen receptor (CAR) targeting CD3 can be susceptible to fratricide because T cells express CD3 on their surface as part of the T cell receptor (TCR)/CD3 complex. To reduce fratricide, CD3 surface expressi...
WO/2024/094527A1	NON-HUMAN VERTEBRATES & CELLS The invention relates to novel means to produce protein multimers that are multimerised in vivo using self-associating multimerisation domains (SAMs), such as self-associating tri- or tetramerisation domains.
WO/2024/097992A2	PARTICLES DISPLAYING ADHESION-MOLECULE FUSIONS Provided herein are particles comprising a fusion molecule comprising an adhesion molecule linked to a costimulatory molecule or an activation molecule, as well as vectors, such as lentiviral vectors, comprising the same, cells comprisin...
WO/2024/094076A1	GIPR BINDING PROTEIN AND USE THEREOF Provided are a GIPR binding protein and a use thereof. Specifically provided are a single-domain antibody specifically binding to a glucose-dependent insulinotropic polypeptide receptor, a derived protein thereof, and a pharmaceutical use.
WO/2024/097875A1	FUSION PROTEINS FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS The present disclosure relates to, inter alia, compositions and methods, including heterologous chimeric proteins that find use, inter alia, in the treatment of nonalcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NAS...
WO/2024/092001A1	CD33 ANTIBODY COMPOSITIONS FOR TREATING ALZHEIMER'S DISEASE The present disclosure provides methods for preventing or treating Alzheimer's disease in a subject, and/or reducing the likelihood or severity of Alzheimer's disease comprising administering to the subject an effective amount of an anti...
WO/2024/091775A1	VARIANT RNA-GUIDED CAS12F4 NUCLEASES AND DNA BINDING PROTEINS Provided are variant Cas12f4 polypeptides, fusion proteins containing variant Cas12f4 polypeptides, nucleic acids encoding variant Cas12f4 polypeptides and fusion proteins, compositions and methods related to those variant Cas12f4 polype...
WO/2024/087761A1	METHOD FOR PRODUCING POLYPEPTIDE FROM RECOMBINANT FUSION PROTEIN AND USE THEREOF The present invention relates to a method for producing a polypeptide from a recombinant fusion protein, and disclosed are a method for producing a polypeptide by means of serially combining multiple protease cleavage sites and polypepti...
WO/2024/088325A1	ANTIBODY AND USE THEREOF The present invention relates to an antibody that specifically binds to CLDN6, and the use thereof.
WO/2024/092095A1	SYSTEMS, METHODS, AND COMPOSITIONS FOR TREATING VASCULAR DISEASE Provided herein are methods and compositions for the diagnosis, prognosis, and treatment of a vascular disease, such as coronary artery disease (CAD), in a subject. In particular, provided are methods and compositions for treating a vasc...
WO/2024/088371A1	ANTIGEN-BINDING PROTEIN TARGETING MSLN An isolated antigen-binding protein capable of targeting MSLN. The isolated antigen-binding protein comprises at least one CDR in an antibody heavy chain variable region VH, and the VH comprises an amino acid sequence represented by any ...
WO/2024/091889A1	METHODS AND COMPOSITIONS COMPRISING FLT3L FOR THE TREATMENT OF WOUNDS Flt3L is a soluble, focused signal that can expand the dendritic cell compartment. The disclosure provides for methods for regenerating tissue, for preventing wound formation, or for treating wounds in a subject. The methods are achieved...
WO/2024/088404A1	ENGINEERED 4-1BBL VARIANTS AND METHODS OF USE THEREOF This disclosure provides engineered 4-1BBL variants, and methods of use thereof.
WO/2024/087405A1	CAS PROTEIN WITH IMPROVED EDITING ACTIVITY AND USE THEREOF A Cas mutant protein. Compared with a parent Cas protein, the Cas mutant protein has a significantly improved editing activity and broad application prospects.

Matches 1 - 50 out of 23,172	1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 >